TALAPRO-3 in mCSPC: Prof. Agarwal discusses the trial results

In this episode, UROONCO PCa associate editor Prof. Claudia Kesch interviews Dr. Neeraj Agarwal, from Dana-Farber Cancer Institute on the recent results of the TALAPRO-3 trial. This trial investigates the efficacy and safety of TALA + ENZA in men with mCSPC bearing HRR gene alterations. Dr. Agarwal elaborates on the rationale of this trial and the key results. They also discuss the control arm in more detail, heterogeneity and HRR alteration, plus clinical practice of managing anaemia and tre...